South Korea
· Delayed Price · Currency is KRW Wonbiogen Statistics
Total Valuation
Wonbiogen has a market cap or net worth of KRW 48.07 billion. The enterprise value is 42.56 billion.
| Market Cap | 48.07B |
| Enterprise Value | 42.56B |
Important Dates
The next estimated earnings date is Friday, November 8, 2024.
| Earnings Date | Nov 8, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
Wonbiogen has 35.47 million shares outstanding. The number of shares has decreased by -0.03% in one year.
| Shares Outstanding | 35.47M |
| Shares Change (YoY) | -0.03% |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | 32.83% |
| Owned by Institutions (%) | n/a |
| Float | 23.83M |
Valuation Ratios
The trailing PE ratio is 11.12.
| PE Ratio | 11.12 |
| Forward PE | n/a |
| PS Ratio | 1.63 |
| PB Ratio | 1.40 |
| P/FCF Ratio | 10.66 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 5.30, with an EV/FCF ratio of 9.44.
| EV / Earnings | 9.33 |
| EV / Sales | 1.45 |
| EV / EBITDA | 5.30 |
| EV / EBIT | 6.66 |
| EV / FCF | 9.44 |
Financial Position
The company has a current ratio of 2.74, with a Debt / Equity ratio of 19.28.
| Current Ratio | 2.74 |
| Quick Ratio | 1.98 |
| Debt / Equity | 19.28 |
| Debt / EBITDA | 0.82 |
| Debt / FCF | 1.48 |
| Interest Coverage | 57.00 |
Financial Efficiency
Return on equity (ROE) is 14.76% and return on invested capital (ROIC) is 9.88%.
| Return on Equity (ROE) | 14.76% |
| Return on Assets (ROA) | 9.19% |
| Return on Capital (ROIC) | 9.88% |
| Revenue Per Employee | n/a |
| Profits Per Employee | n/a |
| Employee Count | n/a |
| Asset Turnover | 0.67 |
| Inventory Turnover | 2.48 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -30.07% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | -30.07% |
| 50-Day Moving Average | 1,520.78 |
| 200-Day Moving Average | 1,643.22 |
| Relative Strength Index (RSI) | 27.89 |
| Average Volume (20 Days) | 81,541 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Wonbiogen had revenue of KRW 29.39 billion and earned 4.56 billion in profits. Earnings per share was 121.84.
| Revenue | 29.39B |
| Gross Profit | 13.93B |
| Operating Income | 6.44B |
| Pretax Income | 5.87B |
| Net Income | 4.56B |
| EBITDA | 8.09B |
| EBIT | 6.44B |
| Earnings Per Share (EPS) | 121.84 |
Balance Sheet
The company has 12.54 billion in cash and 6.67 billion in debt, giving a net cash position of 5.88 billion or 165.69 per share.
| Cash & Cash Equivalents | 12.54B |
| Total Debt | 6.67B |
| Net Cash | 5.88B |
| Net Cash Per Share | 165.69 |
| Equity (Book Value) | 34.58B |
| Book Value Per Share | 964.42 |
| Working Capital | 15.37B |
Cash Flow
In the last 12 months, operating cash flow was 6.05 billion and capital expenditures -1.54 billion, giving a free cash flow of 4.51 billion.
| Operating Cash Flow | 6.05B |
| Capital Expenditures | -1.54B |
| Free Cash Flow | 4.51B |
| FCF Per Share | 127.15 |
Margins
Gross margin is 47.40%, with operating and profit margins of 21.92% and 15.52%.
| Gross Margin | 47.40% |
| Operating Margin | 21.92% |
| Pretax Margin | 19.99% |
| Profit Margin | 15.52% |
| EBITDA Margin | 27.51% |
| EBIT Margin | 21.92% |
| FCF Margin | 15.35% |
Dividends & Yields
This stock pays an annual dividend of 20.00, which amounts to a dividend yield of 1.46%.
| Dividend Per Share | 20.00 |
| Dividend Yield | 1.46% |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | 2 |
| Payout Ratio | 15.55% |
| Buyback Yield | 0.03% |
| Shareholder Yield | 1.49% |
| Earnings Yield | 8.99% |
| FCF Yield | 9.38% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |